Healthcare Companies Announce Upcoming Earnings Schedules, and Receive FDA Approvals and Clearances - Analyst Notes on WellPoint, Anacor, NeuroMetrix, Ophthotech and Emergent BioSolutions

NEW YORK, July 11, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding WellPoint Inc. (NYSE: WLP), Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC), NeuroMetrix Inc. (NASDAQ: NURO), Ophthotech Corporation (NASDAQ: OPHT) and Emergent BioSolutions, Inc. (NYSE: EBS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4686-100free.

--
WellPoint Inc. Analyst Notes
On July 1, 2014, WellPoint Inc. (WellPoint) announced that the Company will release its Q2 2014 financial results at 6:00 a.m. EDT on July 30, 2014. Additionally, the Company stated that during a conference call at 8:30 a.m. EDT on the same day, WellPoint management will review its results and provide an outlook. The call will be available through a live webcast on the Company's website, and a webcast replay will also be available following the call. The full analyst notes on WellPoint are available to download free of charge at:

http://www.analystsreview.com/Jul-11-2014/WLP/report.pdf

--
Anacor Pharmaceuticals, Inc. Analyst Notes
On July 8, 2014, Anacor Pharmaceuticals, Inc. (Anacor) announced that the Company's New Drug Application for KERYDIN™ (tavaborole) topical solution, 5%, has received an approval from the U.S. Food and Drug Administration (FDA). According to the Company, KERYDIN™ (tavaborole) topical solution, 5% is the first oxaborole antifungal approved for the topical treatment of onychomycosis of the toenails. Company Chief Commercial Officer, Vince Ippolito, stated, "KERYDIN was designed to be convenient for patients to use and has demonstrated efficacy in the treatment of the fungal infection, thus allowing growth of new uninfected nail. In market research conducted by Anacor, KERYDIN's product profile was received with great enthusiasm by the participating physicians and we believe this response demonstrates the need for a safe topical treatment for onychomycosis of the toenails." The full analyst notes on Anacor are available to download free of charge at:

http://www.analystsreview.com/Jul-11-2014/ANAC/report.pdf

--
NeuroMetrix Inc. Analyst Notes
On July 8, 2014, NeuroMetrix Inc. (NeuroMetrix) announced that the U.S. Food and Drug Administration (FDA) has given 510(k) clearance (K140333) on the Company's wearable technology for treatment of chronic pain for over-the-counter use. According to the Company, the SENSUS device is lightweight and can be worn during the day while active, and at night while sleeping. Additionally, the Company stated that the device is based on wearable technology, presently deployed in NeuroMetrix's SENSUS® Pain Management System, utilizing comfortable, non-invasive electrical stimulation of sensory nerves to induce safe and effective pain relief. Company President and CEO, Shai N. Gozani, M.D., Ph.D., said, "Patient response to SENSUS, our prescription wearable device for treatment of chronic pain, has been very positive since it was launched in early 2013. The ability to offer both prescription and over-the-counter products will give us maximal market exposure and allow us to reach more people with chronic pain. We anticipate a commercial launch in 2015." The full analyst notes on NeuroMetrix are available to download free of charge at:

http://www.analystsreview.com/Jul-11-2014/NURO/report.pdf

--
Ophthotech Corporation Analyst Notes
On July 8, 2014, Ophthotech Corporation's (Ophthotech) stock went up by 5.78%, closing at $41.92 per share. Over the last three months of trading, Ophthotech stock has increased significantly by 33.89%, much higher compared to the Nasdaq Composite which has increased by 6.76% over the same duration of time. The full analyst notes on Ophthotech are available to download free of charge at:

http://www.analystsreview.com/Jul-11-2014/OPHT/report.pdf

--
Emergent BioSolutions, Inc. Analyst Notes
On July 8, 2014, Emergent BioSolutions, Inc.'s (Emergent BioSolutions) stock increased slightly by 0.30%, ending the day at $23.13 per share. However over the last six months, the Company shares have dipped 6.62%. In comparison, the Dow Jones Industrial Average has increased 2.27% over the same period of time. The full analyst notes on Emergent BioSolutions are available to download free of charge at:

http://www.analystsreview.com/Jul-11-2014/EBS/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsReview.com

SOURCE Analysts Review